AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3068098
Drug: Tinidazole 2
RxNorm normalized name: tinidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 2 g as a single dose
Trial: 29088579
Drug: FX006 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FX006 32 mg
Trial: 27049269
Drug: Fentanyl (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.5 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Trial: 27049269
Drug: Remifentanil (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.25 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Trial: 21296333
Drug: Dronedarone 400
RxNorm normalized name: dronedarone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone 400 mg b.i.d.
Trial: 8943972
Drug: Antroduodenal manometry
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRADUODENAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antroduodenal manometry in parenteral-nutrition-dependent children
Trial: 8458317
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral vitamin K1 supplement (average 88 micrograms)
Trial: 2429279
Drug: Placebo infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions and tablets given at the same schedule as SPG
Trial: 25933493
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d of α-linolenic acid (ALA) for 60 days
Trial: 23042976
Drug: Peginterferon therapy
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon therapy
Trial: 21554881
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of arginine vasopressin (AVP) during tasks without social evaluative threat.
Trial: 11970745
Drug: Exemestane (EXE)
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane (EXE) 25 mg/day
Trial: 7673540
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (BT)
Trial: 7673540
Drug: Combined dermatological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dermatological educational program and cognitive-behavioral treatment (DEBT)
Trial: 19261275
Drug: Sequential timed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential timed natural intercourse
Trial: 16709314
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 g/day subcutaneously)
Trial: 16602632
Drug: Fluvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin treatment
Trial: 3364074
Drug: Reaferon (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reaferon (all doses)
Trial: 24002145
Drug: Stabilized hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stabilized hyaluronic acid-based gel (Restylane® Vital Light) administered via micropuncture injector
Trial: 17011942
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus pravastatin (10-20 mg daily)
Trial: 12590005
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus Kava-Kava 200 mg/day
Trial: 10813713
Drug: GM-CSF administered
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF administered at a dose of 5 microg/kg/day at 10 p.m.
Trial: 8623944
Drug: Lidocaine 40
RxNorm normalized name: lidocaine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 40 mg added to 180 mg propofol
Trial: 1449302
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of metoprolol (control group)
Trial: 26166140
Drug: Celecoxib (200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200mg daily)
Trial: 26166140
Drug: Loxoprofen (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxoprofen (180 mg daily) plus Lansoprazole (15mg daily)
Trial: 15545669
Drug: Sequential radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radiotherapy (SEQ RT)
Trial: 11932900
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CT and Tc-MIBI SPECT
Trial: 1090416
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg lorazepam intravenously
Trial: 24097843
Drug: Raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (400 mg twice daily)
Trial: 30732618
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment protocol (2 μg/kg)
Trial: 19376306
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel therapy (additional loading dose followed by 150 mg daily for 6 months)
Trial: 19376306
Drug: Standard maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard maintenance clopidogrel therapy (75 mg daily for 6 months)
Trial: 11292151
Drug: Virosome subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosome subunit vaccine (v-SUV)
Trial: 7029236
Drug: Whole virus
RxNorm normalized name: rabies, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole virus vaccine (WVV)
Trial: 9389880
Drug: Polyunsaturated fatty
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyunsaturated fatty acids (PUFA) in the form of capsules and margarine
Trial: 2412042
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg b.i.d.)
Trial: 29099926
Drug: Prepubertal Class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepubertal Class II treatment with removable functional appliances
Trial: 19549433
Drug: Somatropin inhalation
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Somatropin inhalation powder (SIP)
Trial: 11879237
Drug: Molecular Adsorbents
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular Adsorbents Recycling System (MARS) treatment
Trial: 9880443
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (L‐GG)
Trial: 7721639
Drug: Pretreatment quality
RxNorm normalized name: Quality Choice Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment quality control review of radiation therapy fields
Trial: 23656594
Drug: Milk with
RxNorm normalized name: BETTERMILK with Glytactin 10PE Powder for Suspension (Orange Creme)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk with L. paracasei SD1
Trial: 19172517
Drug: Pitavastatin 2
RxNorm normalized name: PITAVASTATIN 2MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg once daily (group A)
Trial: 19172517
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 1800 mg daily (group B)
Trial: 19172517
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of pitavastatin and EPA (group C)
Trial: 16848361
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy after radical prostatectomy
Trial: 11069375
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy alone
Trial: 16848361
Drug: Adjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormonal therapy (combined with prostatectomy and radiotherapy)
Trial: 14693305
Drug: Stevioside (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stevioside (500 mg, 3 times daily for 2 years)
Trial: 10978399
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 (60 mg/day)
Trial: 1345022
Drug: Apulein cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apulein cream
Trial: 29607554
Drug: Hydrocortisone ointment
RxNorm normalized name: Hydrocortisone Ointment
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone ointment
Trial: 25690268
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment and diabetes education
Trial: 25690268
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (at screening)
Trial: 22116471
Drug: Cognitive treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive treatment, exposure treatment, or their combination with fluvoxamine
Trial: 20518948
Drug: ERN/LRPT (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERN/LRPT (1 g) plus statin, advanced to ERN/LRPT (2 g) after 4 weeks
Trial: 12397697
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II type 1 receptor antagonist losartan
Trial: 12397697
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme (ACE) inhibitor enalapril
Trial: 12397697
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist amlodipine
Trial: 10457578
Drug: Interferential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential therapy
Trial: 7015692
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vincristine, nitrosomethylurea, and dactinomycin
Trial: 7015692
Drug: DTIC (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC (150 mg/m2 iv days 1, 2, 3, 4, 5)
Trial: 21247622
Drug: Synchrovine® (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchrovine® (two doses of PGF(2α), 7 d apart)
Trial: 15643648
Drug: Transdiagnostic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic treatment for anxiety
Trial: 3391736
Drug: PPA 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA 37.5 mg (immediate release formulation)
Trial: 31294771
Drug: Ranibizumab, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab, 0.5 mg, every 4 weeks
Trial: 31294771
Drug: Aflibercept, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept, 0.5 mg, every 4 weeks
Trial: 28751662
Drug: L p
RxNorm normalized name: Midol PM
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L p -Adaptation method
Trial: 29111115
Drug: Aprepitant (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (125 mg/day)
Trial: 21050274
Drug: 0.50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg/kg YS
Trial: 15496223
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Donepezil + Risperidone and Donepezil only)
Trial: 9736892
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy intervention (twice‐weekly for 18 weeks)
Trial: 3276492
Drug: Thymopentin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (50 mg, intravenous injections, three times weekly)
Trial: 26166526
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education group (received oral health education for 3 years)
Trial: 22069382
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low-frequency right prefrontal followed by low-frequency left temporal rTMS
Trial: 26792348
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline injection)
Trial: 9598455
Drug: WR 238605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR 238605 (doses ranging from 4 to 600 mg)
Trial: 3280829
Drug: Chlorthalidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (25 or 50 mg daily)
Trial: 3280829
Drug: Magnesium hydroxide
RxNorm normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium hydroxide (650 or 1300 mg daily)
Trial: 29024892
Drug: Life Review
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life Review Therapy (4-week duration)
Trial: 24201679
Drug: Weekly supervised
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supervised pelvic floor muscle training class and daily home exercise for 16 weeks.
Trial: 7649712
Drug: Glycosaminoglycan polysulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycosaminoglycan polysulfate (GAGPS) injections
Trial: 2745867
Drug: Computer-aided pharmacokinetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-aided pharmacokinetic method of aminoglycoside dose prediction
Trial: 27107097
Drug: Esomeprazole-based regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole-based regimen (20 mg)
Trial: 27107097
Drug: Omeprazole-based regimen
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole-based regimen (20 mg)
Trial: 14633079
Drug: Terazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (1 mg, twice-a-day) for 12 weeks
Trial: 10963819
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing of glibenclamide
Trial: 10963819
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily dosing of glibenclamide
Trial: 8909669
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine (0.15 mg/kg)
Trial: 30088695
Drug: Concurrent smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent smoking status verified using expired carbon monoxide
Trial: 23063221
Drug: Combined NAI
RxNorm normalized name: Shan Nai
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined NAI and PUI after CaOH(2) medication
Trial: 10617169
Drug: Paroxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (40 mg)
Trial: 24653510
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg/d)
Trial: 16125367
Drug: TAU (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (Treatment as Usual) - standard treatment without special training
Trial: 7857100
Drug: UFT with
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT with leucovorin tablet (400 mg/day of UFT with 20 mg/day of leucovorin)
Trial: 7857100
Drug: UFT alone
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT alone (400 mg/day of UFT)
Trial: 1678445
Drug: Ampicillin (25‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (25‐30 mg/kg body weight three times daily for 5 days) plus supportive care
Trial: 31077610
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) + Parent Psychoeducation (TEPSI)
Trial: 29423579
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral rectus sheath block (US-BRSB) with 30 ml of 0.25% ropivacaine
Trial: 16815141
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 500 mcg, twice daily for 2 weeks
Trial: 9212476
Drug: Non-priming group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-priming group (n = 20) received mivacurium 0.25 mg/kg
Trial: 8402628
Drug: Vorozole racemate
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorozole racemate 1 mg
Trial: 8402628
Drug: Vorozole racemate
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorozole racemate 5 mg
Trial: 24839862
Drug: Sucrose drink
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose drink (100 g in 250 ml)
Trial: 24839862
Drug: Placebo (artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (artificial sweeteners in 250 ml)
Trial: 18665934
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus yogurt (yogurt group, n = 168)
Trial: 18665934
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy only (control group, n = 179)
Trial: 11276273
Drug: Nabumetone (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (1,000 to 2,000 mg/d)
Trial: 11276273
Drug: Diclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (100 to 150 mg/d)
Trial: 7696941
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg aspirin daily
Trial: 22850220
Drug: Infusions prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions prepared by pharmacy and industry
Trial: 15589470
Drug: Tacrolimus and
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus and steroids
Trial: 15589470
Drug: Ciclosporin A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin A, steroids, azathioprine, and ATG
Trial: 12405554
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) of 5 mg of LY 156735
Trial: 8590851
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of rhG-CSF post chemotherapy with ProMACE/CytaBOM regimen
Trial: 8590851
Drug: Previous study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous study without rhG-CSF administration
Trial: 1674632
Drug: Carvedilol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (5 mg)
Trial: 2975095
Drug: Nifedipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (2 mg)
Trial: 2609718
Drug: Nifedipine +
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine + Propranolol (2 mg + 5 mg)
Trial: 991149
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of agents including DTIC
Trial: 23035175
Drug: ACE527 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE527 vaccine
Trial: 17244104
Drug: Morphine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (administered intravenously)
Trial: 18313505
Drug: Other agents
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other agents
Trial: 23387822
Drug: Intravenous t‐PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous t‐PA
Trial: 3315193
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide and lorazepam (M+L)
Trial: 3315193
Drug: Prochlorperazine and
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prochlorperazine and lorazepam (P+L)
Trial: 28025924
Drug: Increased number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased number of chronic medications
Trial: 18326619
Drug: Novel galactooligosaccharide
RxNorm normalized name: fructooligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel galactooligosaccharide (0, 3.6, or 7 g/d)
Trial: 18326619
Drug: Novel galactooligosaccharide
RxNorm normalized name: fructooligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel galactooligosaccharide (7 g/d)
Trial: 7493372
Drug: IFN-alpha treatment
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha treatment